84-1175-58　IGFBP4 (Insulin-like Growth Factor-binding Protein 4, IBP-4, IGF-binding Protein 4, IGFBP-4, IBP4) 100ul　I7661-16P1

特徴

• The insulin like growth factors (IGFs) are the major growth- promoting factors in the plasma.
• IGFs are secreted by a variety of cells and exert a multitude of effects on cellular survival, growth and differentiation.
• The A and B domains of IGFs are identical to insulin.
• IGF initiates their biological action through binding to the type IGF receptor (IGF-1R), a heterotrimeric protein complex with a tyrosine kinase activity.
• The IGF-IIR lacks the kinase activity and is actually identical to the mannose- 6-phophate receptor.
• Unlike most other peptide hormones, IGFs are complexed with specific binding proteins in the plasma known IGF Binding proteins (IGFBPs).
• At least 6 related IGFBPs (IGFBP1-6) have been well characterized.
• Recently, IGFBP-7/Mac25/prostacyclin-stimulating factor (PSF)/tumor adhesion factor (TAF) was originally identified as a cDNA derived from leptomeninges.
• These proteins are present in plasma in high concentration as compared to the membrane IGFRs.
• Therefore, IGFBPs have the potential to modulate the IGF action.
• IGFBPs have been shown to either inhibit or stimulate the IGF effects.
• The primary structures of mammalian IGFBPs appear to contain three distinct domains of roughly equivalent sizes: the conserved N-terminal domain, the highly variable mid region, and the conserved C-terminal domain.
• Human IGFBPs share approximately 36% identity.
• Insulin-like growth factor binding protein-4 (IGFBP-4, 22-237aa mature protein, protein accession # P22692) is expressed in multiple tissues including adrenal, testis, spleen, heart, lung, kidney, liver, stomach, hypothalamus, and brain cortex.
• High expression levels are found in the non-paranchymal cells of the liver.4 IGFBP-4 is the predominant IGFBP expressed by human osteoblast-like cells and is also expressed in skin fibroblasts.
• Applications:Suitable for use in ELISA, Immunoprecipitation and Western Blot.
• Other applications not tested.
• Recommended Dilution:Western Blot: 1:1000-1:2000ELISA: 1:10,000 (50-100ng control antigen/well)
• Immunoprecipitation: 2-10 ul per assayOptimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Aliquots are stable for at least 12 months.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.